BIENAIME JEAN JACQUES 4
4 · Keros Therapeutics, Inc. · Filed Jun 5, 2024
Insider Transaction Report
Form 4
BIENAIME JEAN JACQUES
Director
Transactions
- Award
Stock Option (right to buy)
2024-06-03+17,600→ 17,600 totalExercise: $48.67Exp: 2034-06-02→ Common Stock (17,600 underlying)
Footnotes (1)
- [F1]One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on September 3, 2024, subject to the Reporting Person continuing to provide service through each such date.